Date: 2016-07-14
Type of information: Commercialisation agreement
Compound: nine biosimilars including biosimilars of adalimumab, bevacizumab and trastuzumab
Company: Amgen (USA - CA) Daiichi Sankyo (Japan)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases
Type agreement: commercialisation
Action mechanism: monoclonal antibody/biosimilar.
Disease:
Details: * On July 14, 2016, Amgen and Daiichi Sankyo announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab. Under the terms of the agreement, Amgen will remain responsible for the development and manufacturing of the biosimilars. Daiichi Sankyo will file for marketing approval and be responsible for distribution and commercialization in Japan, while Amgen will have a limited right to co-promote the products.
Amgen will retain all additional distribution and commercialization rights for the biosimilar programs outside of Japan.
Financial terms: Specific financial terms of the agreement were not disclosed.
Latest news:
